Free Trial
NYSEAMERICAN:IBIO

iBio (IBIO) Stock Price, News & Analysis

$0.92 +0.07 (+8.50%)
As of 04/25/2025 04:00 PM Eastern

About iBio Stock (NYSEAMERICAN:IBIO)

Key Stats

Today's Range
$0.81
$0.93
50-Day Range
$0.70
$6.41
52-Week Range
$0.64
$6.89
Volume
520,218 shs
Average Volume
686,663 shs
Market Capitalization
$3.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

iBio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
2nd Percentile Overall Score

IBIO MarketRank™: 

iBio scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for iBio.

  • Percentage of Shares Shorted

    12.57% of the float of iBio has been sold short.
  • Short Interest Ratio / Days to Cover

    iBio has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in iBio has recently increased by 37.50%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    iBio does not currently pay a dividend.

  • Dividend Growth

    iBio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.57% of the float of iBio has been sold short.
  • Short Interest Ratio / Days to Cover

    iBio has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in iBio has recently increased by 37.50%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    10 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iBio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.12% of the stock of iBio is held by insiders.

  • Percentage Held by Institutions

    Only 7.90% of the stock of iBio is held by institutions.

  • Read more about iBio's insider trading history.
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Stock News Headlines

iBio announces data from non-human primate PK study of IBIO-600
iBio to transfer listing to Nasdaq from NYSE
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
IBio Expands Cardiometabolic And Obesity Program
See More Headlines

IBIO Stock Analysis - Frequently Asked Questions

iBio's stock was trading at $2.42 at the start of the year. Since then, IBIO shares have decreased by 62.0% and is now trading at $0.9190.
View the best growth stocks for 2025 here
.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Mesoblast (MESO), Mobileye Global (MBLY), KULR Technology Group (KULR), IonQ (IONQ), Guardforce AI (GFAI), Fastly (FSLY) and Exscientia (EXAI).

Company Calendar

Today
4/26/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:IBIO
Employees
100
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-65,010,000.00
Pretax Margin
-41,546.00%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Price / Cash Flow
N/A
Book Value
$15.15 per share
Price / Book
0.06

Miscellaneous

Free Float
3,445,000
Market Cap
$3.20 million
Optionable
N/A
Beta
-3.77
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NYSEAMERICAN:IBIO) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners